Despite International Agreement On Fusion, Future Of Research In U.S. Remains Murky

U.S. Remains Murky Date: December 7, 1992 It's the worst of times, but in some ways it's also the best of times for fusion researchers. On the upside is a complex, four- party agreement that was signed in July, commiting the world fusion community to a collaborative effort to design the next- generation fusion experiment. The United States is joining Japan, Europe, and Russia to design the International Thermonuclear Experimental Reactor (ITER). The bad news is that the agreement is only to

Written byScott Veggeberg
| 8 min read

Register for free to listen to this article
Listen with Speechify
0:00
8:00
Share

U.S. Remains Murky Date: December 7, 1992

It's the worst of times, but in some ways it's also the best of times for fusion researchers. On the upside is a complex, four- party agreement that was signed in July, commiting the world fusion community to a collaborative effort to design the next- generation fusion experiment. The United States is joining Japan, Europe, and Russia to design the International Thermonuclear Experimental Reactor (ITER).

The bad news is that the agreement is only to design the plant, not to actually build it. And, aside from this project, physicists complain that there really are no other major new experiments planned for U.S. researchers. Budget constraints have forced the domestic fusion effort to survive on experimental facilities built in earlier years and to put all its eggs into one basket, the tokamak design--a doughnut-shaped device that confines the fusion plasma via a magnetic field.

...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies